From a therapeutic perspective, the efficacy of Rituximab (RTX) has been proven when used as a first-line treatment of standard cases of MN, i.e. young adults presenting with nephrotic syndrome and normal renal function, having positive anti-PLA2R antibodies [13]. Here, PLA2R1 is linked to nephrotic syndrome.